Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Exclusion Criteria

• •Have taken medications to lower blood sugar other than insulin glargine, pioglitazone, or metformin in the 3 months before entering the study for more than a 1-week period, or within 1 week of entering the study.
• •Have had more than one episode of major (severe) hypoglycemia in the 6 months before entering the study.
• •Are pregnant or intend to become pregnant during the study or are sexually active women not actively practicing birth control.
• •Women who are breastfeeding.
• •Have any significant diseases of the blood, heart, kidney, gastrointestinal system, or other significant diseases such as cancer.
• •Have had a kidney transplant or are currently on kidney dialysis.
• •Have a cancer that's never been treated, that's currently being treated, or that was diagnosed within the last 5 years.
• •Have had a bad reaction to exenatide in the past or have a condition that is not recommended to be exposed to exenatide or any of exenatide's other ingredients.
• •Have used a drug for weight loss in the 3 months before entering the study for more than a 1-week period, or within 1 month of entering the study.
• •Are currently on a weight-loss program or have been on one within 3 months of entering the study.
• •Have had a blood transfusion or severe blood loss within 3 months of entering the study.
• •Are taking systemic glucocorticoids or have received systemic glucocorticoids within 8 weeks of entering the study.
• •Have an irregular sleep cycle (for example, sleeping during the day and working during the night).
• •Have a history of pancreatitis.
• •Have received treatment with an experimental drug within 30 days of entering the study.
• •If on metformin, have a condition that is not recommended to be exposed to metformin, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis.
• •If on metformin, have had a radiologic contrast study performed within 48 hours of entering the study.
• •If on pioglitazone, have a condition that is not recommended to be exposed to pioglitazone, including congestive heart failure, or are taking pioglitazone at a dose that is not approved for use with insulin.